Chemistry:Eltanexor
From HandWiki
Eltanexor (KPT-8602) is an experimental drug which is a Selective Inhibitor of Nuclear Export (SINE), acting as a selective inhibitor of the XPO1 nuclear export protein. Levels of this protein are frequently elevated in numerous forms of cancer, such as prostate cancer and multiple myeloma, and eltanexor has shown promising results in several clinical trials, mainly as a combination treatment with other drugs rather than a sole agent.[1][2][3][4][5][6][7][8] It has also shown potential for the treatment of osteoporosis.[9]
See also
References
- ↑ "Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression". Oncotarget 9 (82): 35327–35342. October 2018. doi:10.18632/oncotarget.26239. PMID 30450161.
- ↑ "Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies". Blood Advances 4 (3): 586–598. February 2020. doi:10.1182/bloodadvances.2019000359. PMID 32045477.
- ↑ "Targeting Nuclear Export Proteins in Multiple Myeloma Therapy". Targeted Oncology 15 (6): 697–708. December 2020. doi:10.1007/s11523-020-00758-2. PMID 33074469.
- ↑ "PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia". Journal of Hematology & Oncology 14 (1). June 2021. doi:10.1186/s13045-021-01114-1. PMID 34167562.
- ↑ "New Approaches to Myelodysplastic Syndrome Treatment". Current Treatment Options in Oncology 23 (5): 668–687. May 2022. doi:10.1007/s11864-022-00965-1. PMID 35320468.
- ↑ "Nuclear Export Inhibitors Selinexor (KPT-330) and Eltanexor (KPT-8602) Provide a Novel Therapy to Reduce Tumor Growth by Induction of PANoptosis". Cell Biochemistry and Biophysics 81 (3): 421–426. September 2023. doi:10.1007/s12013-023-01135-2. PMID 37126200.
- ↑ "The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials". Clinical and Translational Medicine 14 (5). May 2024. doi:10.1002/ctm2.1684. PMID 38783482.
- ↑ "A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1". Cells 13 (7): 632. April 2024. doi:10.3390/cells13070632. PMID 38607071.
- ↑ "Anti-Osteoclast Effect of Exportin-1 Inhibitor Eltanexor on Osteoporosis Depends on Nuclear Accumulation of IκBα-NF-κB p65 Complex". Frontiers in Pharmacology 13. 2022. doi:10.3389/fphar.2022.896108. PMID 36110547.
 |  |
